Haymana C, et al. – Researchers tried to find out the impact of testosterone replacement therapy (TRT) on vitamin D and Fibroblast growth factor–23 (FGF–23) levels along with endothelial functions and insulin resistance in hypogonadal patients. The outcomes displayed that a short term testosterone replacement therapy (TRT) increases plasma FGF–23 and asymmetric dimethylarginine (ADMA) levels, in young, treatment naive patients with congenital hypogonadotrophic hypogonadism (CHH). Whether this is an early implication of TRT related adverse effects in this very young and treatment naïve population of CHH is not clear.

Methods

• Researchers included patients with congenital hypogonadotrophic hypogonadism (CHH) (n=32, age 20.6 ±1.58 years).
• Furthermore, TRT was implemented in transdermal form.
• They assessed demographic parameters, FGF–23, 25(OH)D3, Asymmetric dimethylarginine (ADMA) and homeostatic model assessment of insulin resistance (HOMA–IR) levels both before and after TRT.

Results

• The evidence showed that ADMA and FGF–23 levels were significantly increased (p=0.03 and p=0.005 respectively), while the 25(OH)D3 and HOMA–IR index were not significantly changed after a follow–up period of 3.63±1.33 months.
• It was showed that the body mass index and waist circumference levels of the patients were also increased (p<0.001 and p=0.02) along with a significant decrease in the HDL cholesterol levels (p=0.006).